MC
Mayuri Charnalia
Research areas: Medicine · Obstetrics and Gynecology · Endometrial and Cervical Cancer Treatments · Advanced Radiotherapy Techniques · Cervical Cancer and HPV Research
0000-0002-0013-0396
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (14)
- Cumulative gastrointestinal adverse events in EMBRACE-I: comparative evaluation of CTCAE vs. MOSES methods in predicting the impact of incident vs. persistent adverse events on quality of life Save
- Normal Tissue Complication Probability models for gastrointestinal toxicity after adjuvant (chemo) radiotherapy for cervical cancer in the PARCER trial Save
- Point S (sigmoid) doses and correlation with late recto-sigmoid adverse events in patients undergoing image-based brachytherapy for cervical cancer: clinical outcomes Save
- Gynaecological reirradiation with image-guided radiotherapy: Tumour Control Probability and Normal Tissue Complication Probability in pre-immunotherapy era Save
- 3426 Risk factors for acute gastrointestinal toxicity in cervix cancer treated with advanced image-guided radiochemotherapy: an EMBRACE-II analysis. Save
- Defining Optimal Nodal Dose for Stage IIIC Cervical Cancer: An Institutional Audit of Patients Treated with Simultaneous Integrated Nodal Boost Save
- RECIST 1.1 versus clinico-radiological response assessment for locally advanced cervical cancer: implications on interpreting survival outcomes of future trials Save
- 2293: Acute gastrointestinal toxicity of concurrent chemoradiation in cervix cancer: EMBRACE-II findings Save
- Repurposing pantoprazole in combination with systemic therapy in advanced head and neck squamous cell carcinoma: a phase I/II randomized study Save
- Late toxicity within a Phase III clinical trial of IG-IMRT in cervix cancer (PARCER): Reanalysis with time weighted adverse event reporting (MOSES) Save
- Patterns of Relapse After Adjuvant Chemoradiation for Cervical Cancer in a Phase 3 Clinical Trial (PARCER): An Evaluation of Updated NRG Oncology/RTOG Target Delineation Guidelines Save
- Months and Severity Score (MOSES) in a Phase III trial (PARCER): A new comprehensive method for reporting adverse events in oncology clinical trials Save
- Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial Save
- Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial Save